TMDX: 2027 growth hinges on heart and lung trials, European expansion, and execution
TransMedics Group, Inc. (TMDX) experienced strong Q3 momentum due to trial progress, liver performance, NOP services, and European operations. Key catalysts for 2027 growth include the successful completion of heart and lung trials and continued European expansion. The primary risk to achieving these goals is effective execution of its strategy.
TransMedics Group (TMDX) Could Be 11% Undervalued As It Raises 2026 Outlook
TransMedics Group (TMDX) has raised its 2026 revenue outlook after reporting strong third-quarter results, indicating better-than-expected performance and earlier contributions from new programs. Despite a recent 30-day share price increase of 29.10%, the stock is still down over the year, yet analysts consider it 11% undervalued with a fair value estimate of $102.55 against a current close of $91.38. The company's potential stems from its scaled transplant services platform, aiming for 60% gross margins and higher transplant volumes.
Will Raised 2026 Guidance Change TransMedics Group (TMDX) Narrative
TransMedics Group (TMDX) recently raised its full-year 2026 revenue guidance to US$764 million - US$774 million, including contributions from PAD Aviation. While this higher forecast indicates management's confidence in continued procedure demand and service adoption, the article emphasizes that the key challenge remains converting this top-line growth into sustainable profitability amidst pressure on margins from higher operating expenses. The raised guidance reinforces the growth aspect of the investment thesis but also sharpens focus on the company's ability to improve net income and earnings per share.
TransMedics Group (NASDAQ:TMDX) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
TransMedics Group (NASDAQ:TMDX) reported strong earnings, but a detailed analysis suggests potential underlying issues. The company's accrual ratio indicates that its reported profits are not fully backed by free cash flow, partly due to a significant tax benefit. If this tax benefit is not recurring, the company's profitability could decrease in the future, suggesting its current earnings may present an overly optimistic view of its sustainable profitability.
TMDX: OCS 2.0, European logistics and kidney expansion underpin the growth outlook
TransMedics Group, Inc. (TMDX) is poised for growth driven by its OCS 2.0 trials for heart and lung outcomes, European logistics expansion, and entry into kidney transplant services. Initial 2027 guidance anticipates 20%-25% revenue growth, with significant contributions from Europe expected from the latter half of 2027. This outlook is based on insights from the Stifel 2026 Healthcare Conference.
A 4,059-share sale is proposed by TransMedics (TMDX) director James R. Tobin.
TransMedics Group, Inc. (TMDX) director James R. Tobin has proposed selling 4,059 common shares with an aggregate market value of $385,467.75, according to a Form 144 notice. The approximate sale date is November 9, 2026, and the shares were acquired as restricted stock from the issuer on three separate occasions between 2024 and 2026. Morgan Stanley Smith Barney LLC is named as the broker for this transaction.
TransMedics Group (NASDAQ:TMDX) Price Target Raised to $88.00
UBS Group raised its price target for TransMedics Group (NASDAQ:TMDX) to $88.00 from $77.00, while maintaining a "neutral" rating. This new target implies a potential downside of 6.19% from the stock's previous close. The medical technology company recently reported strong quarterly earnings, beating analyst estimates with an EPS of $0.51 and revenue of $203.01 million, representing a 41.1% year-over-year increase.
TransMedics Group (NASDAQ:TMDX) Stock Gets Price Target Boost from JPMorgan Chase & Co.
JPMorgan Chase & Co. raised its price target for TransMedics Group (NASDAQ:TMDX) stock from $73.00 to $85.00, while maintaining a "neutral" rating. Despite the upgrade, the new target implies a potential downside of 3.67% from the company's previous close. The company recently surpassed quarterly earnings expectations, reporting EPS of $0.51 and revenue of $203.01 million, significantly exceeding analyst estimates.
TransMedics Group (TMDX) Could Be 14% Undervalued As Mixed Earnings Reignite Valuation Debate
TransMedics Group (TMDX) has recently seen its stock rise significantly after mixed third-quarter earnings, leading to a debate over its true valuation. While analysts on Simply Wall St suggest the stock is 14% undervalued with a fair value of $102.55, its P/E ratio is lower than industry averages, indicating potential for a re-rating or reduced valuation risk. The company's expansion into new organ types, particularly OCS Kidney, is a key factor influencing future earnings power and valuation.
TransMedics Sets 2026 Revenue Guidance at $764 Million to $774 Million Including PAD
TransMedics Group, Inc. has set its 2026 revenue guidance at $764 million to $774 million, which includes approximately $14 million from PAD Aviation. Excluding PAD Aviation, the company's guidance is $750 million to $760 million, an increase from the previous range of $737 million to $757 million. The CEO noted that the third quarter of 2026 was the strongest in TransMedics’ history for both revenue and case volume.
TransMedics Group (NASDAQ:TMDX) Raised to "Hold" at Wall Street Zen
Wall Street Zen upgraded TransMedics Group (NASDAQ:TMDX) from a "sell" to a "hold" rating. The company reported strong third-quarter results, beating analyst estimates with $203.0 million in revenue and $0.51 EPS, and raised its 2026 revenue outlook. Despite these positive financial indicators, some key catalysts have been delayed to early 2027.
JP Morgan maintains TransMedics Group at Neutral, raises price target to $85 from $73
JP Morgan has maintained its "Neutral" rating on TransMedics Group (TMDX) but increased its price target to $85 from $73, representing a 16.4% rise. This new target implies a 3.7% downside from the stock's November 6 closing price of $88.24. Other recent analyst actions on TransMedics Group include "Buy" ratings from Needham and Canaccord Genuity with price targets of $110 and $120, respectively, and an "Overweight" initiation from Barclays with a $120 price target.
TransMedics Group Q3 Earnings Call Highlights
TransMedics Group reported record third-quarter revenue of $203 million, a 41% increase year-over-year, and raised its full-year 2026 revenue guidance to $764 million to $774 million. The company saw strong growth in its liver and heart transplant segments, despite a decline in overall U.S. deceased donor volume. TransMedics also provided updates on its ENHANCE Heart and DENOVO Lung programs, targeting new indications and expanded adoption in 2027.
Needham maintains TransMedics Group at Buy, raises price target to $110 from $106
Needham has reiterated its Buy rating for TransMedics Group (TMDX) and increased its price target to $110 from $106, representing a 3.8% rise. This new price target suggests a potential upside of 59.5% from the closing price of $68.98 on November 5. Investors can find more detailed price target data and analyst recommendations on TradingView's platform.
TransMedics Group (NASDAQ:TMDX) Given New $110.00 Price Target at Needham & Company LLC
Needham & Company LLC has raised its price target for TransMedics Group (NASDAQ:TMDX) to $110.00, maintaining a "buy" rating. This adjustment comes after TransMedics reported strong quarterly revenue of $203 million, a 41.1% increase year-over-year, and an EPS of $0.51, surpassing analyst estimates. The company also increased its 2026 revenue guidance, reflecting confidence in its continued growth, despite a slight decline in EPS from the previous year.
TransMedics Reports Third Quarter 2026 Financial Results
TransMedics Group, Inc. reported strong third-quarter 2026 financial results, with total revenue up 41% to $203.0 million and net income of $17.1 million. The company raised its full-year 2026 revenue guidance to between $764-$774 million, driven by increasing organ transplant volumes and strategic investments like PAD Aviation. TransMedics also announced significant progress in its clinical trials and European expansion, positioning itself for continued growth.
TransMedics Stock Gains Attention After Revenue Guidance Raise
TransMedics Group reported strong Q3 2026 revenue of US$203.01 million and raised its full-year revenue guidance, driven by record case volumes and increased adoption of its organ care and logistics platform. Despite a decline in industry donor volumes, the company's expanded Liver and Heart offerings, along with its logistics network, suggest it is capturing a larger market share. While sales are up, net income was lower year-over-year, indicating a focus on execution and cost discipline will be key to converting current spending into stable earnings.
TransMedics (TMDX) Q3 2026 Earnings Call Transcript
TransMedics (TMDX) reported record Q3 2026 revenue of $203 million, a 41% year-over-year increase, driven by strong growth in Liver and Heart OCS case volumes and market share gains despite a decline in overall U.S. disease donor volume. The company raised its full-year 2026 revenue guidance to $764 million to $774 million and highlighted progress in its ENHANCE Heart Part A and Part B trials, DENOVO Lung program, OCS Kidney development, and expansion of its NOP services and transplant logistics network into Europe, including winning its first European tender in Italy.
TransMedics Group (NASDAQ:TMDX) Announces Quarterly Earnings Results, Beats Expectations By $0.21 EPS
TransMedics Group (NASDAQ:TMDX) announced strong quarterly earnings, beating analyst expectations with an EPS of $0.51 against a consensus of $0.30, and revenue reaching a record $203.01 million. The company raised its 2026 revenue guidance to $764 million–$774 million, driven by increased organ transplantation volumes and new growth opportunities in heart and lung programs. Despite a slight decline in gross margin due to a larger share of lower-margin services, management expressed a conservative but optimistic outlook for the fourth quarter.
12 Health Care Stocks Moving In Thursday's After-Market Session
This article details the performance of 12 healthcare stocks during Thursday's after-market session. Six stocks, including TransMedics Group and InnovAge Holding, saw gains primarily due to recent earnings reports. Conversely, six other stocks, such as Inovio Pharmaceuticals and Dentsply Sirona, experienced declines, also frequently following earnings announcements.
TransMedics Reports Third Quarter 2026 Financial Results
TransMedics Group, Inc. reported strong financial results for the third quarter of 2026, with total revenue increasing by 41% to $203.0 million, driven by organic growth and contributions from PAD Aviation. The company raised its full-year 2026 revenue guidance to between $764-$774 million, citing record revenue and case volume, as well as progress in clinical trials and European expansion. Key catalysts for future growth include IDE approvals for ENHANCE Heart Part B and DENOVO Lung trials, and plans to launch OCS NOP in several European countries.
TransMedics Group Jumps 8.4% Amid Sector-Wide Rally
TransMedics Group (TMDX) saw its shares surge by 8.4% to $73.00 on Wednesday, participating in a strong sector-wide rally among medical device companies. This increase, alongside similar gains in at least eight peer companies, suggests a broader institutional rotation into the medical device space rather than company-specific news. Investors are advised to monitor whether this sector strength is sustainable or merely a short-term bounce.
TransMedics Group (NASDAQ:TMDX) Upgraded to Hold at Zacks Research
Zacks Research upgraded TransMedics Group (NASDAQ:TMDX) from a "strong sell" to a "hold" rating. The consensus analyst rating for TMDX is "hold" with a target price of $115.60. The company's stock opened at $67.34, significantly below its 52-week high, and reported Q3 revenue of $189.95 million (up 20.7% year-over-year) but missed EPS estimates at $0.44.
TransMedics Group, Inc. (1TMDX.MI) Seasonal returns chart
This article from Yahoo Finance presents a seasonal returns chart for TransMedics Group, Inc. (1TMDX.MI). It also notes the company's Q3 2026 earnings call scheduled for November 5, 2026, at 22:30 CET, and provides current stock performance data. The seasonality chart displays the average monthly price return for TransMedics from 2025 to 2026.
TransMedics Group, Inc. (1TMDX.MI) Seasonal Returns Chart - Yahoo Finance
The article provides a seasonal returns chart for TransMedics Group, Inc. (1TMDX.MI), indicating average monthly price returns from 2025 to 2026. It also notes the upcoming Q3 2026 earnings call for the company on November 5, 2026. The stock was trading at 69.64 EUR, down 2.08% at market close on October 2.
TransMedics Group, Inc. (1TMDX.MI) Seasonal returns chart
This article provides a seasonal returns chart for TransMedics Group, Inc. (1TMDX.MI), displaying the average monthly price return from 2025 to 2026. It also notes the upcoming Q3 2026 earnings call scheduled for November 5, 2026, at 10:30 pm GMT+1. The current stock quote shows 1TMDX.MI at 69.64 EUR, down 2.08% as of October 2, 2026.
Trek Financial LLC Acquires New Holdings in TransMedics Group, Inc. $TMDX
Trek Financial LLC has acquired a new stake in TransMedics Group, Inc. (NASDAQ:TMDX), purchasing 143,667 shares valued at approximately $11.99 million, representing a 0.42% ownership. This comes as institutional investors and hedge funds collectively own 99.67% of the company. TransMedics recently reported quarterly revenue of $189.95 million, exceeding estimates, but missed earnings per share forecasts with $0.44.
TMDX Investors Have Opportunity to Join TransMedics Group, Inc. Fraud Investigation with SBS Law
Schall, Brown & Schwartz LLP (SBS) has announced an investigation into TransMedics Group, Inc. (NASDAQ: TMDX) for potential breaches of fiduciary duty by its directors and management. The firm is inviting investors who have suffered losses to participate in the investigation. SBS specializes in securities class action lawsuits and shareholder rights litigation, representing investors globally.
TransMedics Group, Inc. (TMDX.MX) Seasonal returns chart
The article provides a seasonal returns chart for TransMedics Group, Inc. (TMDX.MX), showing the average monthly price return between 2025 and 2026. It also includes current stock performance and upcoming earnings call information for the company.
TransMedics Group, Inc. (TMDX) Seasonal Returns Chart - Yahoo Finance
This article from Yahoo Finance provides a seasonal returns chart for TransMedics Group, Inc. (TMDX). It displays the average monthly price return for TMDX from 2019 to 2026, offering historical seasonality data. The stock's real-time price and after-hours trading information are also included.
TransMedics Group, Inc. (TMDX) Seasonal returns chart
This article provides a seasonal returns chart for TransMedics Group, Inc. (TMDX), showing average monthly price returns from 2019 to 2026. It includes current stock price data and after-hours trading information for TMDX. The page also features navigation to other financial data like news, charts, statistics, and analysis.
A 22,969-unit stock grant goes to TransMedics (TMDX) CFO Fernando N. Araujo alongside options.
TransMedics Group, Inc. CFO Fernando N. Araujo received 22,969 restricted stock units and an option for 34,419 shares on October 28, 2026. The option has an exercise price of $66.90 per share and vests 25% on September 21, 2027, with the remainder vesting monthly over three years. This grant is subject to his continued service to the company.
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
TransMedics Group, Inc. announced the grant of non-qualified stock options and restricted stock units (RSUs) to nine new employees on October 28, 2026, as a material inducement for their employment. These grants, including awards to CFO Fernando Araujo, were approved by the Compensation Committee and comply with Nasdaq Listing Rule 5635(c)(4) and the Company's Inducement Plan. The options and RSUs have specific vesting schedules tied to continued employment.
TransMedics Group, Inc. (NASDAQ:TMDX) Stock Has Average Price Target of $115.60 According to Brokerages
TransMedics Group, Inc. (NASDAQ:TMDX) has an average 12-month price target of $115.60 from brokerages, with a consensus "Hold" rating. Despite recent revenue growth exceeding estimates, the company missed adjusted earnings expectations. Insider activity shows a director purchasing shares, and institutional investors hold a significant portion of the stock.
TransMedics to Present at Upcoming Investor Conferences
TransMedics Group, Inc. (Nasdaq: TMDX), a medical technology company focused on organ transplant therapy, announced its participation in three upcoming investor conferences. Management will hold a fireside chat at the Stifel 2026 Healthcare Conference on November 10, 2026, present at the Jefferies Global Healthcare Conference on November 17, 2026, and attend the Piper Sandler 38th Annual Healthcare Conference on December 1, 2026. Live and archived webcasts of the fireside chats will be available on the Investors section of the TransMedics website.
TransMedics to Present at Upcoming Investor Conferences
TransMedics Group, Inc. announced its participation in three upcoming investor conferences. Management will participate in fireside chats at the Stifel 2026 Healthcare Conference on November 10, the Jefferies Global Healthcare Conference on November 17, and the Piper Sandler 38th Annual Healthcare Conference on December 1, 2026. Webcasts of these events will be available on the company's investor relations website.
TransMedics Faces A Margin Test As PAD Aviation And Kidney Spending Hit Results
TransMedics is facing a crucial margin test as increased spending on OCS Kidney and the acquisition of PAD Aviation are impacting its financial results, despite strong revenue growth. Investors are watching to see if the margin reset is a temporary investment phase or if spending is outpacing returns. The company's tone on its year-end exit rate and progress on clinical trials and new catalysts will be key in its upcoming third-quarter report.
TransMedics Group, Inc. Estimates – NASDAQ:TMDX
This page from TradingView provides financial estimates and data for TransMedics Group, Inc. (NASDAQ: TMDX). Users can explore reported financial data and analyst estimates across various financial statements and visualize trends over time. The platform also allows comparison of actual results with average, high, and low estimates for the company.
A 4:30 p.m. ET call will accompany TransMedics' Q3 results on Nov. 5
TransMedics Group (TMDX) announced it will release its third-quarter 2026 financial results after market close on November 5, 2026. The company's management team will host a conference call at 4:30 p.m. ET (1:30 p.m. PT) to discuss the results. A live and archived webcast of the event will be available on the "Investors" section of the TransMedics website.
TransMedics to Report Third Quarter 2026 Financial Results on November 5, 2026
TransMedics Group, Inc. (Nasdaq: TMDX) announced it will release its third-quarter 2026 financial results after market close on Thursday, November 5, 2026. The company's management will host a conference call at 4:30 p.m. ET / 1:30 p.m. PT to discuss the results, with a live and archived webcast available on their investor relations website.
TransMedics Group, Inc. (8T8.F) Analyst insights, Price targets and Recommendations
This article provides a summary of analyst recommendations and price targets for TransMedics Group, Inc. (8T8.F). It lists recent upgrades, downgrades, and maintained ratings from various financial institutions, including Canaccord Genuity, Barclays, TD Cowen, UBS, Piper Sandler, and Needham. The information covers analyst actions from August to October 2026.
Stifel holds TransMedics Group stock at USD 65.00 amid competition
Stifel has maintained a Hold rating and a USD 65.00 price target for TransMedics Group (TMDX) stock, citing long-term competition concerns. This comes despite the company reporting a 21.00 percent year-over-year revenue increase to USD 189.95 million in the second quarter. Other analysts, like Canaccord and Barclays, have set higher price targets, while TransMedics Group expects to announce third-quarter earnings around November 4, 2026.
TransMedics Group Inc (8T8.MU) stock price, news, quote and history
This Yahoo Finance page provides an overview of TransMedics Group Inc (8T8.MU) stock, including its current price, recent news, and performance data. The stock is listed on the Munich exchange, trading at 64.12 EUR, down 3.72%. Recent news articles from Simply Wall St. and GuruFocus discuss the stock's valuation, earnings, and strategic highlights.
Stifel holds TransMedics stock at Hold amid competition concerns
Stifel maintains a Hold rating and a $65.00 price target for TransMedics (TMDX) due to potential long-term competitive pressures despite the company's strong revenue growth. While TransMedics reported a 21% increase in Q2 2026 revenue to $189.9 million, its net income and adjusted diluted EPS declined. Other analysts like Canaccord and Barclays have differing views, with targets ranging from $94.00 to $120.00, highlighting a valuation debate driven by both growth and profitability concerns.
17,734 Shares in TransMedics Group, Inc. $TMDX Purchased by Annex Advisory Services LLC
Annex Advisory Services LLC has acquired a new stake of 17,734 shares in TransMedics Group, Inc. (TMDX), valued at approximately $1.48 million. This purchase contributes to the 99.67% institutional ownership of the company. Despite reporting quarterly revenue above estimates, TransMedics' EPS missed consensus, and its shares opened significantly below their 12-month high, leading analysts to maintain a consensus "Hold" rating.
TransMedics Group, Inc. (TMDX) Stock forecasts
The article "TransMedics Group, Inc. (TMDX) Stock forecasts" is severely truncated and contains almost no substantive information. It appears to be a placeholder or a corrupted page from Yahoo Finance, primarily displaying navigation elements, market data summaries, and various links rather than actual content about TransMedics Group, Inc.
Argus lowers TransMedics stock target to USD 76.00
Argus has lowered its stock target for TransMedics to USD 76.00, set on October 7, 2026, despite the company reporting second-quarter 2026 revenue of USD 189.9 million, a 21% increase year over year. TransMedics also raised the lower end of its full-year 2026 revenue guidance to USD 737 million. The company, which operates in medical devices with its Organ Care System, will report third-quarter results on November 4, 2026.
TransMedics Group, Inc. (TMDX) Options Chain - Yahoo Finance
This Yahoo Finance page provides options chain data for TransMedics Group, Inc. (TMDX). It shows real-time stock prices and delayed options data, noting that no call or put options are currently available for the specified date of November 6, 2026. The page also includes general market data and company-specific financial information.
TMDX Maintained by Canaccord Genuity -- Price Target Lowered to $94
Canaccord Genuity has maintained a "Buy" rating for TransMedics Group (TMDX) but lowered its price target slightly from $95.00 to $94.00. Despite this, GuruFocus indicates TMDX is significantly undervalued by 50.9% and shows strong growth potential with a GF Score™ of 72/100, though profitability remains an area for improvement. Insider buying activity of $109,058 further suggests confidence in the company's future prospects.
TransMedics Group (NASDAQ:TMDX) Stock Gets Price Target Trim from Canaccord Genuity Group
Canaccord Genuity Group has lowered its price target for TransMedics Group (NASDAQ:TMDX) from $95 to $94 but maintained a "buy" rating, indicating an 18.54% potential upside. Despite this, the stock holds an overall "hold" consensus rating among analysts with an average price target of $115.60. TransMedics Group's latest quarterly revenue exceeded estimates, though adjusted earnings per share missed the consensus forecast.